The news that the drug Vytorin' may not be very effective for its advertised purpose has created a crisis for its manufacturers.
Vytorin and the ENHANCE Study
The news that the drug Vytorin' may not be very effective for its advertised purpose has created a crisis for its manufacturers. Critics claim the results of a clinical trial of the medication's efficacy were released months, if not years, after the drug companies knew their product was not what they had originally claimed. Now, government oversight agencies are investigating the possibility that the drug's manufacturers are guilty of insider trading, medical test manipulation and/or false advertising. In addition, shareholders are upset and consumers are suing.
This premium content is locked for LawJournalNewsletters subscribers only
ENJOY UNLIMITED ACCESS TO THE SINGLE SOURCE OF OBJECTIVE LEGAL ANALYSIS, PRACTICAL INSIGHTS, AND NEWS IN LawJournalNewsletters
- Stay current on the latest information, rulings, regulations, and trends
- Includes practical, must-have information on copyrights, royalties, AI, and more
- Tap into expert guidance from top entertainment lawyers and experts
Already have an account? Sign In Now
For enterprise-wide or corporate access, please contact Customer Service at [email protected] or call 1-877-256-2473.






